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Objectives. We aimed to investigate the impact of intravascular
ultrasound (IVUS)-guided stent implantation on the 6-month
restenosis rate, which has not yet been fully established in
randomized trials.
Background. The 6-month angiographic restenosis rate was
compared in patients with symptomatic ischemic heart disease
who were randomly allocated to angioplasty and stent deployment,
with versus without IVUS guidance.
Methods. After successful stent implantation, patients were
randomized into two groups: Group A had no further dilation, and
Group B had additional balloon dilation until achievement of
IVUS criterion for stent expansion. The study group consisted of
164 patients, assuming a 50% reduction of the restenosis rate in
Group B (15% vs. 30%) (alpha 5 10%, beta 5 20%).
Results. We enrolled 155 patients. Overdilation was carried out
in 31 (39%) of 79 Group B patients, with the IVUS criterion being
achieved in 63 (80%) of 79. No significant difference was observed
in the minimal luminal diameter (MLD), but the stent lumen
cross-sectional area (CSA) was significantly larger in Group B
(mean 6 SD) (7.16 6 2.48 vs. 7.95 6 2.21 mm2, p 5 0.04). At 6
months, there was no significant difference in the restenosis rate,
(28.8% [21 of 73] in Group A vs. 22.5% [16 of 71] in Group B, p 5
0.25), but according to the observed difference in the restenosis
rate, the power of the study was only 40%. The difference in MLD
was also nonsignificant (1.60 6 0.65 mm in Group A vs. 1.70 6
0.64 mm in Group B, p 5 0.20), whereas the lumen CSA was 20%
larger in the IVUS-guided group (4.47 6 2.59 vs. 5.36 6 2.81 mm2,
p 5 0.03). Lumen CSA was the only predictor of restenosis by
multivariate logistic regression analysis.
Conclusions. A nonsignificant 6.3% absolute reduction in the
restenosis rate and a nonsignificant difference in MLD were
observed in this study. Nonetheless, we still cannot rule out a
beneficial effect of IVUS guidance, although this may have gone
undetected owing to a lack of statistical power. A significant
increase was observed in immediate and 6-month lumen size, as
detected by IVUS, indicating that ultrasound guidance in stent
deployment may be beneficial.
(J Am Coll Cardiol 1998;32:320–8)
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Stents are increasingly used because they have been shown to
reduce the 6-month restenosis rate (1–3). However, after stent
implantation, intravascular ultrasound (IVUS) studies have
demonstrated that inadequate stent deployment is not infre-
quent, despite an apparently adequate angiographic result, and
that it can be responsible for acute or subacute stent throm-
bosis (4–6). It has been shown that it is possible to optimize
stent deployment with IVUS-guided overdilations, thanks to
bigger balloons or higher inflation pressures. After IVUS-
guided overdilation, intrastent lumen cross-sectional area
(CSA) and stent minimal lumen diameter (MLD) were shown
to increase by as much as 11% to 80% (4,7,8). This made it
possible to omit oral anticoagulation and to reduce bleeding
complication rates without increasing the stent subacute
thrombosis rate (8,9), paving the way for the use of systematic
high inflation pressure for stent deployment without IVUS
guidance with favorable immediate and 1-month clinical out-
comes (10,11). However, it was shown that even after high
inflation pressures, suboptimal stent deployment can still be
observed with IVUS (6).
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The impact of this immediate lumen enlargement on the
long-term restenosis rate and on the target lesion revascular-
ization rate (12–15) has been established but not supported by
randomized trials. Therefore, we conducted a randomized
study comparing two groups of patients who had angioplasty
and stent deployment, with or without IVUS guidance, to
determine the long-term benefit of IVUS guidance in this
setting.
Methods
This was a multicenter, randomized, single-blinded study.
Participating centers and investigators were selected on the
basis of their experience with coronary angioplasty and IVUS
and their involvement in clinical trials. The protocol was
approved by the investigators and the Ethics Committee of the
University Hospital Saint-Jacques, Besanc¸on, France.
Study design. The study group consisted of patients with
symptomatic coronary artery disease with demonstrable isch-
emia and single-vessel or native multivessel disease with .70%
stenosis of the target lesion, who had percutaneous translumi-
nal coronary angioplasty (PTCA) followed by stent implanta-
tion for extensive dissection, a suboptimal result or as a
primary choice.
The inclusion criteria were 1) single ,20-mm long stent
deployment with a Palmaz-Schatz stent (Johnson & Johnson),
MicroStent (Applied Vascular Engineering), NIR stent (Bos-
ton Scientific Corporation) or Freedom stent (Global Thera-
peutic); 2) balloon/artery ratio for stent placement between 1.0
and 1.2; 3) balloon inflation pressure .12 atm for deployment
of a Palmaz-Schatz or NIR stent and .9 atm for deployment
of a premounted AVE or Freedom stent; 4) optimal angio-
graphic result after stent implantation, without dissection or
residual stenosis .20% as assessed visually or with on-line
quantitative coronary angiography (QCA); and 5) written
informed consent for participation in the study. The exclusion
criteria were 1) vessel diameter ,3.0 mm by visual estimation
or on-line QCA; 2) coronary lesion .15 mm in length; 3)
previous bypass surgery; 4) contraindication to antiplatelet
therapy (aspirin or ticlopidine); 5) treatment of acute or
chronic total occusion; 6) saphenous vein graft stenosis; and 7)
recent (,7 days) acute coronary syndromes.
Randomization into two groups was done after stent im-
plantation, once the angiographic result was judged satisfac-
tory. IVUS imaging was performed in all patients, but no
further dilation was performed, irrespective of the IVUS
findings in the non-IVUS guidance group (Group A), whereas
additional balloon inflations were performed until the criterion
for stent expansion on IVUS imaging was reached in the IVUS
guidance group (Group B). The ratio of intrastent CSA to the
average of the proximal and distal reference lumen CSA, with
a cutoff point at 80%, was chosen as the ultrasound criterion
for optimal stent deployment.
Ultrasound procedures and measurements. IVUS imaging
was done using a 30-MHz mechanical ultrasound transducer
(Sonicath, 3.5F Boston Scientific Corporation) and an ultra-
sound scanner (Sonos 2400A, Hewlett Packard). After optimi-
zation of the machine setting, images were recorded on a
S-VHS videotape recorder, after an intracoronary bolus injec-
tion of 0.5 mg of isosorbide dinitrate and during a slow
continuous manual pullback. At 6-month follow-up angiogra-
phy, IVUS imaging was repeated using the same technique in
both groups.
On-line ultrasound assessment was performed in diastole. It
was carried out in Group B patients only and repeated after
each overinflation, if any, until the criterion for optimal stent
deployment was achieved. The lumen CSA at the stent level
was assessed by planimetry at the interface of the blood and
the stent, at multiple levels (at least three), and the smallest
area was chosen. The proximal and distal reference lumen
areas were also measured by manual planimetry. The reference
segments were selected as the most normal-looking cross
section within 10 mm proximal and distal to the stent.
Off-line ultrasound measurements were performed by a
single observer using the same technique as for on-line analy-
sis. To reduce the variability, all IVUS measurements were
repeated, and the average of the two values was used in the
analysis. Reliability of off-line IVUS measurements, which
includes image selection variability, was assessed using an
average of two measurements by a single observer, with the
intraclass correlation coefficient, and the standard deviation of
the mean difference from repeat measurements of the lumen
CSA in 50 patients. The intraclass correlation coefficient (ratio
of interpatient variance to interpatient plus intraobserver
variance) of the lumen CSA measurements at the stent level
was 0.94 (mean 6 SD between two measurements 5 0.06 6 0.8
mm2) and at the reference level 0.92 (mean 6 SD, 0.05 6 0.9
mm2).
Angiographic procedure and analysis. Two orthogonal
views of the coronary artery segment submitted to balloon
angioplasty and stent implantation were taken before and after
angioplasty and at 6-month control angiography. QCA was
carried out using the empty tip of the 7F guiding catheter for
calibration. Angiograms were analyzed off-line using an auto-
mated edge detection algorithm (CAAS II, Pie Medical, The
Netherlands) by an operator who had no knowledge of the
IVUS data. The MLD, proximal and distal reference diameters
and percent stenosis were determined for every pair of views
and averaged. In addition, the length of diseased segments
submitted to balloon angioplasty and stent implantation were
determined before angioplasty from QCA measurements.
Postprocedure medication and clinical follow-up. Heparin
therapy was stopped within 24 h after angioplasty, and patients
Abbreviations and Acronyms
CSA 5 cross-sectional area
IVUS 5 intravascular ultrasound
MLD 5 minimal lumen diameter
PTCA 5 percutaneous transluminal coronary angioplasty
QCA 5 quantitative coronary angiography
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were discharged on day 2 with orders to take a daily dose of
aspirin (250 mg) and ticlopidine (500 mg) for 1 month. Clinical
outcome was assessed during the hospital stay and up to 6
months later, taking into account major clinical events like
death, myocardial infarction (Q or non–Q wave), the need for
emergency bypass surgery or repeat angioplasty, recurrent
angina, hemorrhagic complications and prolonged hospital
stay (.3 days). The definition of these events is the same as
used in other studies (11).
Study end points. The primary end point was the 6-month
restenosis rate, defined as .50% narrowing at the stent site or
5 mm proximal or distal to the stent, as assessed by QCA.
Secondary study end points were the 6-month angiographic
MLD and 6-month lumen CSA, as assessed by IVUS.
Statistical methods. Given the complexity, the increased
duration and the extra cost of the procedure with the use of
IVUS, it was postulated that a reduction of at least 50% of the
restenosis rate in the IVUS-guided group would be clinically
relevant. Given the restenosis rate observed in the stent group
of the STent REStenosis Study (2), we assumed that a 30%
restenosis rate would be observed in the control group and
15% in IVUS-guided group. The sample size was calculated
accordingly; two groups of 82 patients were needed (alpha
10%, beta 20%, one-sided situation). With such a sample size,
the power of the study was 85% for the detection of a 0.2-mm
difference in 6-month MLD and 90% for the detection of a
2-mm2 difference in 6-month lumen CSA. Continuous data
were presented as the mean value 6 SD and qualitative data as
a percentage. Comparisons between the two groups were
made: in qualitative data using the Fisher exact probabilities
test or the likelihood ratio chi-square test and in quantitative
data using the Student t test. Intraindividual comparisons were
done using the Wilcoxon signed-rank test. Multivariate logistic
regression analysis was used to identify predictors of the
angiographic restenosis rate (variables with a p value ,0.05 by
univariate analysis were entered into the multivariate analysis).
A p value ,0.05 was considered significant. Statistical analysis
was performed with BMDP 90 statistical software (University
of California, Berkeley). Analysis was done according to the
intention-to-treat principle.
Results
Between January 1995 and February 1997, 155 patients
were included in the study.
Protocol violations. Four ineligible patients (two in each
group) were enrolled. In one patient, the treated lesion was a
total occlusion. Three patients had previous bypass surgery,
but the target lesion was located on a native artery in all three.
Furthermore, three patients from Group A underwent addi-
tional stent implantation after randomization. In these pa-
tients, IVUS imaging showed incomplete coverage of the
lesion at the edge of the stent, with significant residual stenosis,
which was not detected angiographically before randomiza-
tion. These patients were maintained in the control group.
Comparability of the two groups before randomization.
There was no significant difference between the groups in
terms of demographic and clinical characteristics (Table 1).
Procedural details and angiographic and IVUS measurements
before angioplasty and after stent deployment (i.e., before
randomization) are given in Table 2. In the whole group, the
mean reference diameter was 2.99 6 0.50 mm. The average
MLD was 0.99 6 0.40 mm before angioplasty and increased to
2.47 6 0.44 mm after angioplasty. There was no significant
difference between the groups in terms of stent type, balloon
size, balloon/artery ratio and angiographic details before
PTCA or in terms of angiographic and IVUS details after stent
implantation.
Feasibility, safety and results of IVUS guidance in stent
deployment. Seventy-nine patients were randomly allocated to
Group B. IVUS imaging was not available because of technical
failure in five patients. On-line analysis showed that the IVUS
criterion was not reached in 31 (39%) of 79 patients who were
subjected to further inflations within the stent. Actually, off-
line measurements showed that 8 of 31 patients submitted to
overdilation had already reached the IVUS criterion before
overdilation was undertaken, and that 5 of 43 patients not
Table 1. Demographic and Clinical Characteristics
Variable
Group A
(n 5 76)
Group B
(n 5 79) p Value
Males 71 (93%) 68 (86%) 0.13*
Mean age (years) 56 6 12 57 6 10 0.28†
Previous infarction 48 (63%) 54 (68%) 0.49*
Diabetes 8 (11%) 9 (11%) 0.93*
Cholesterol 52 (68%) 54 (68%) 0.94*
High blood pressure 26 (34%) 24 (30%) 0.67*
Smoker 51 (67%) 55 (70%) 0.94*
CCS functional status
Silent ischemia 24 (33%) 20 (25%)
Class I 25 (32%) 30 (38%)
Class II 21 (28%) 19 (24%) 0.69‡
Class III 5 (6%) 7 (9%)
Class IV 1 (1%) 3 (4%)
}
Lesion site
LAD 36 (47%) 38 (48%)
LCx 8 (11%) 9 (11%) 0.70‡
RCA 32 (42%) 32 (41%) }
AHA/ACC lesion type
A 8 (11%) 5 (6%)
B1 31 (41%) 40 (51%)
B2 26 (34%) 27 (34%) 0.43‡
C 11 (14%) 7 (9%) }
Lesion length 8.05 6 4.05 7.72 6 3.53 0.59†
(min, max) (3.0, 19.2) (3.0, 20.0)
Mean LVEF†† 51 6 9 53 6 13 0.75†
*Result of the Fisher exact probabilities test. †Result of the Student t test.
‡Result of the likelihood ratio chi-square test. Data presented are the number
(%) of patients or the mean value 6 SD. AHA/ACC 5 American Heart
Association/American College of Cardiology; CCS 5 Canadian Cardiovascular
Society; LAD 5 left anterior descending coronary artery; LCx 5 left circumflex
coronary artery; LVEF 5 Left ventricular ejection fraction; RCA 5 right
coronary artery.
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submitted to overdilation had a lumen ratio ,0.8. Overdilation
was carried out with a bigger noncompliant balloon (10.5 mm
in diameter) in seven patients, with the same noncompliant
balloon as used for stent deployment but at a higher pressure
in eight patients and with the same compliant balloon as used
for stent deployment but at a higher pressure in 16 patients. In
10 patients, a second overdilation was necessary after a first
attempt failed to achieve the criterion for optimal stent
deployment.
In 7 of 31 patients, the procedure was stopped even though
the IVUS criterion was not reached. The cause was angio-
graphic evidence of overexpansion of the stent in four patients.
In three other patients with a Palmaz-Schatz stent, the smallest
lumen area was measured at the central articulation of the
stent, so that overdilation with larger balloons did not result in
lumen enlargement and did not allow achievement of the
IVUS criterion.
No major complication was induced by overdilation. Three
cases of coronary nonocclusive dissection (type C) distal to the
stent occurred and was treated by additional prolonged bal-
loon inflation in one patient and by additional stent implanta-
tion in two patients.
In patients submitted to overdilation, significant enlarge-
ment was observed, both in MLD (from 2.31 6 0.45 to 2.62 6
0.42 mm, mean difference 0.31 6 0.30 mm, p , 0.001) and in
IVUS stent lumen CSA (from 6.90 6 1.81 to 7.49 6 1.61 mm2,
mean difference 0.59 6 0.68 mm2, p , 0.003) (Table 3).
After completion of the procedure, a significant difference
appeared between the two groups at the highest balloon
pressure used (11.7 6 2.1 vs. 13.2 6 2.3 atm, p 5 0.04) (Table
4), but without a significant difference in the balloon/artery
ratio. No significant difference was observed in MLD or
residual stenosis, but acute angiographic gain was significantly
higher in Group B (1.45 6 0.53 mm in group A vs. 1.62 6
Table 2. Procedural, Angiographic and Intravascular Ultrasound Data, Before Angioplasty and After
Stent Implantation (i.e., Before Randomization)
Variable
Group A
(n 5 76)
Group B
(n 5 79) p Value
Type of stent
Palmaz-Schatz 32 (42%) 42 (53%)
AVE MicroStent 18 (24%) 18 (23%)
0.48*NIR Scimed 21 (28%) 16 (20%)
Freedom Global Therapeutic 5 (7%) 3 (4%) }
Mean length of stent (mm) 15.4 6 5.6 15.8 6 4.9 0.42†
Balloon size (mm)
3.0 mm 37 (49%) 35 (44%)
3.5 mm 31 (41%) 40 (51%) 0.29*
4.0 mm 8 (11%) 4 (5%) }
Mean 3.30 6 0.33 3.30 6 0.29 0.93†
Balloon/artery ratio 1.14 6 0.15 1.13 6 0.16 0.99†
Mean balloon pressure (atm) 11.72 6 2.09 11.67 6 3.03 0.85†
Angiography before PTCA
Proximal reference diameter (mm) 3.06 6 0.59 2.94 6 0.57 0.38†
Distal reference diameter (mm) 2.88 6 0.58 2.90 6 0.49 0.56†
%Stenosis 64 6 12 65 6 11 0.51†
MLD (mm) 1.02 6 0.44 0.96 6 0.37 0.39†
Angiography after stent implantation
Proximal reference diameter‡ (mm) 2.94 6 0.51 3.02 6 0.49 0.37†
Distal reference diameter§ (mm) 2.77 6 0.56 2.85 6 0.49 0.36†
%Stenosis 19 6 9 19 6 10 0.92†
MLD (mm) 2.46 6 0.46 2.48 6 0.43 0.73†
IVUS after stent implantation
Proximal reference diameter lumen CSA\ (mm2) 8.72 6 2.51 8.62 6 2.62 0.75†
Distal reference diameter lumen CSA¶ (mm2) 7.96 6 2.66 8.45 6 3.03 0.44†
Stent lumen CSA# (mm2) 7.16 6 2.48 6.89 6 2.71 0.35†
*Result of the likelihood ratio chi-square test. †Result of the Student t test. MLD 5 minimal luminal diameter
(assessed by quantitative coronary analysis [QCA]). ‡Proximal reference diameter 5 lumen diameter of the reference
segment proximal to the stent (assessed by QCA). ‡Distal reference diameter 5 lumen diameter of the reference segment
distal to the stent (assessed by QCA). ¶Proximal reference diameter lumen CSA 5 lumen cross-sectional area of the
reference segment proximal to the stent (assessed by IVUS). \Distal reference diameter lumen CSA 5 lumen
cross-sectional area of the reference segment distal to the stent (assessed by IVUS). #Stent lumen CSA 5 minimal
intrastent lumen cross-sectional area (assessed by IVUS). Quantitative values normally distributed and non-normally
distributed are expressed as the value 6 mean SD. Other data are expressed as the number (%) of patients. CSA 5
cross-sectional area; IVUS 5 intravascular ultrasound; MLD 5 minimal lumen diameter; PTCA 5 percutaneous
transluminal coronary angioplasty.
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0.43 mm in Group B, p 5 0.04). Stent lumen CSA was also
significantly larger in Group B than in Group A (7.16 6 2.48
vs. 7.95 6 2.21, p 5 0.04). In Group B, 63 (80%) of 79 patients
had reached the IVUS criterion at the end of the procedure, as
compared with 45 (59%) of 76 patients in Group A, without
IVUS-guided overdilation (p , 0.01).
Six-month follow-up. Six-month clinical follow-up was
completed for all patients. Two died during the follow-up
period—one from noncardiac death (Group B) and one from
a massive pulmonary embolism 4 months after stent implanta-
tion (Group A). Nine patients refused angiographic follow-up.
None had recurrence of angina, and an exercise stress test was
negative in four. Recurrent chest pain requiring early angio-
graphic control (between 12 and 20 weeks after angioplasty)
occurred in 12 patients. Four had intrastent restenosis (includ-
ing one occlusion). Eight had no restenosis, four of whom
underwent a second control angiography at 6 months. Control
angiography was obtained in 144 patients (93%) between 5 and
7 months after stent implantation (Table 4). The restenosis
rate was not significantly different between the two groups—
28.8% (21 of 73) in Group A versus 22.5% (16 of 71) in Group
B (p 5 0.25). There was no significant difference in MLD,
average percent stenosis, late loss or net gain between the two
groups.
IVUS images were available in 137 of 144 patients with
angiographic follow-up (69 patients in Group A and 68 in
Group B). In four patients with .70% angiographic restenosis
(two in each group), the IVUS transducer failed to cross the
lesion, and a value of 1 mm2 was assigned as 6-month stent
lumen CSA. There was a significantly larger FU stent lumen
CSA in Group B—4.47 6 2.59 versus 5.36 6 2.81 mm2 (p 5
0.03). Bivariate regression analysis showed a significant corre-
lation between the two measurements of lumen CSA at the
stent level (r 5 0.55, p , 0.001). Cumulative distribution
curves of MLD and lumen CSA before and after stent implan-
tation and at follow-up are presented in Figures 1 and 2.
Univariate analysis was carried out to compare patients
with and without restenosis on angiography. A significant
difference was observed with regard to lesion site, postproce-
dure in-stent lumen size (MLD or stent lumen CSA), prepro-
Table 3. Angiographic and Intravascular Ultrasound Data From 31 Patients Submitted to Overdilation (n 5 31)
Variable
Before
Angioplasty (a) Randomization (b) Final Result (c)
p Value*
(a) vs. (b) (b) vs. (c)
Proximal reference diameter (mm) 3.01 6 0.61 2.97 6 0.52 3.00 6 0.44 0.85 0.37
Distal reference diameter (mm) 2.98 6 0.50 2.88 6 0.52 2.94 6 0.41 0.43 0.20
MLD (mm) 0.91 6 0.31 2.31 6 0.45 2.62 6 0.42 ,0.001 0.001
%Stenosis 65 6 10 22 6 9 16 6 9 ,0.001 0.008
Proximal reference diameter lumen CSA (mm2) No data 9.31 6 2.94 9.56 6 2.68 0.58
Distal reference diameter lumen CSA (mm2) No data 9.17 6 3.56 9.38 6 3.94 0.41
Stent lumen CSA (mm2) No data 6.90 6 1.81 7.49 6 1.61 0.003
*Result of the Wilcoxon signed-rank test. Data presented are the mean value 6 SD. Abbreviations as in Table 2.
Table 4. Angiographic and Intravascular Ultrasound Results at End of Procedure and at 6 Months
Variable
Immediate Results 6-Month Results
Group A
(n 5 76)
Group B
(n 5 79) p Value
Group A
(n 5 73)
Group B
(n 5 71) p Value
Balloon/artery ratio 1.17 6 0.12 1.22 6 0.13 0.45* — —
Inflation pressure (atm) 11.7 6 2.1 13.2 6 2.3 0.04* — —
Angiographic result
Proximal reference diameter (mm) 2.94 6 0.51 3.00 6 0.46 0.59* 2.82 6 0.46 2.74 6 0.49 0.29
Distal reference diameter (mm) 2.77 6 0.56 2.88 6 0.41 0.24* 2.62 6 0.52 2.72 6 0.51 0.22*
MLD (mm) 2.46 6 0.46 2.57 6 0.41 0.11* 1.60 6 0.65 1.70 6 0.64 0.20*
%Stenosis 19 6 9 16 6 10 0.35* 42 6 18 38 6 20 0.13*
Early gain (mm) 1.45 6 0.53 1.62 6 0.43 0.04* — —
Net gain (mm) — — — 0.60 6 0.70 0.74 6 0.65 0.85*
Late loss (mm) — — — 0.86 6 0.57 0.87 6 0.57 0.85*
Restenosis rate (%) — — — 28.8 (21/73) 22.5 (16/71) 0.25†
IVUS result
Proximal reference diameter lumen CSA (mm2) 8.72 6 2.51 8.80 6 3.08 0.85* 8.24 6 2.86 8.49 6 2.69 0.85*
Distal reference diameter lumen CSA (mm2) 7.96 6 2.66 8.54 6 3.15 0.23* 8.20 6 3.8 8.41 6 2.72 0.43*
Stent lumen CSA (mm2) 7.16 6 2.48 7.95 6 2.21 0.04* 4.47 6 2.59 5.36 6 2.81 0.03*
%IVUS criteria achieved 45 (59%) 63 (80%) 0.001†
*Result of the Student t test. †Result of the Fisher exact probabilities test. Data presented are the mean value 6 SD or as the number (%) of patients. Abbreviations
as in Table 2.
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cedure vessel size (angiographic distal reference diameter)
before angioplasty and balloon size (Table 5). These variables
were entered into a logistic regression model, as well as group
assignment and age, which were forced into the model despite
being nonsignificant. The only independent predictor of resten-
osis was postprocedure lumen CSA at the stent level (OR 0.70
per additional mm2 in stent lumen CSA, 95% confidence
interval 0.47 to 0.93) (Table 6).
Discussion
The main findings of this study are: 1) despite the use of
high inflation pressures for stent implantation, the IVUS
criteria for optimal stent deployment were not achieved in
;60% of the patients even with an adequate angiographic
appearance of the stented lesion; 2) IVUS-guided overinfla-
tion led to a significant early increase in MLD and lumen CSA,
resulting in the whole group in a significant increase in lumen
CSA, but a nonsignificant increase in MLD; 3) a nonsignifi-
cant, 6-month absolute 6.3% reduction in the restenosis rate at
6 months and a nonsignificant 6-month 0.1-mm increase in
MLD; and 4) a significant 19.9% increase in lumen CSA.
These results were obtained in patients routinely submitted
to PTCA and stent implantation whose indication was based
on the currently admitted indications (i.e., extensive dissection,
suboptimal results or as a primary choice in arteries $3 mm in
diameter) (1,2). Moreover, the clinical status, types of stent
used, indication for stent implantation, balloon/artery ratio
and balloon inflation pressure were identical to those used in
our daily practice, so that we can assume that there was no
major difference between the study patients and patients
routinely submitted to PTCA and stent implantation in the
institutions participating in the trial but not included in the
study.
In addition, the study design guaranteed the comparability
of the two groups, as randomization took place only after the
optimal post-stent angiographic result was obtained. Lastly,
the use of high inflation pressures and balloon/artery ratio
.1.1 for stent implantation guaranteed that the stents were not
systematically underexpanded before IVUS imaging—this be-
Figure 1. Cumulative distribution curves of an-
giographic MLD (horizontal axis, in mm) before
angioplasty, after stent deployment and at
follow-up in the two groups. Open circles 5
Group A; open triangles 5 Group B.
Figure 2. Cumulative distribution
curves of minimal lumen CSA
(horizontal axis, in mm2), as as-
sessed by IVUS, after stent deploy-
ment and at follow-up in the two
groups. Open circles 5 Group A;
open triangles 5 Group B.
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ing a known bias capable of influencing the need for subse-
quent overexpansion (8).
Finally, these results were obtained using a simple IVUS
criterion for optimal stent deployment, which has previously
been shown to be associated with an acceptable benefit to risk
ratio and which is currently widely accepted (12,16,17,18). This
IVUS criterion, compared with more complex criteria, led to a
reduction in discrepancies between on-line and off-line analy-
sis, which depend on the reliability of IVUS measurements
(satisfactory in our experience) (17,18).
Impact of IVUS guidance on immediate results. According
to our IVUS criteria, 31 (39%) of 79 Group B patients needed
overdilation, which resulted in a lower than expected increase
in intrastent lumen size, 13% in MLD and 8.5% in stent lumen
CSA. Nonetheless, this was sufficient to significantly increase
angiographic early gain and stent lumen CSA in the whole
group. A preliminary report of a randomized trial using
another IVUS criterion showed that 29% of patients needed
overdilation, resulting in a 24.3% increase in lumen CSA and
a 0.32-mm increase in MLD (19).
The fact that, in our study, the IVUS criterion was not
achieved in a small but sizeable proportion of patients (7 of 31)
despite high overdilation pressure and balloon/artery ratio
.1.15 may have contributed to the rather modest increase in
intrastent lumen size. This fact is consistent with the findings of
a preliminary report from another randomized trial in which
the IVUS criteria were achieved in only 68% of cases after
IVUS guidance (20). The inability to achieve the IVUS
criterion may depend on the criterion chosen and also on the
type of stent used, coil stents being more prone to recoil than
tubular slotted stents; plaque prolapse at the central articula-
tion of Palmaz-Schatz stents can also prevent achievement of
the target lumen size despite bigger balloons and higher
inflation pressure (16).
Table 5. Univariate Analysis: Comparison of Patients With Versus Without Restenosis
Variable
Patients With
Restenosis
(n 5 37)
Patients Without
Restenosis
(n 5 107) p Value
Age (years) 59 6 11 55 6 11 0.06*
Male 34 (92%) 94 (88%) 0.71†
Diabetes 5 (13%) 11 (10%) 0.80†
Cholesterol 23 (62%) 75 (70%) 0.28†
High blood pressure 15 (41%) 32 (30%) 0.30†
Smoker 27 (73%) 69 (64%) 0.40†
Lesion site
LAD 25 (67%) 44 (41%)
LCx 3 (8%) 12 (11%) 0.02‡
RCA 9 (24%) 51 (48%) }
AHA/ACC lesion type
A 5 (14%) 8 (7%)
B1 15 (41%) 49 (46%) 0.60‡
B2 12 (32%) 38 (36%)
C 5 (14%) 12 (11%) }
Lesion length (mm) 7.91 6 4.08 8.08 6 3.78 0.85*
Balloon size (mm) 3.18 6 0.32 3.34 6 0.31 0.01*
Balloon/artery ratio 1.22 6 0.14 1.18 6 0.14 0.13*
Proximal reference diameter (mm) before PTCA 2.89 6 0.48 3.04 6 0.62 0.17*
Distal reference diameter (mm) before PTCA 2.69 6 0.40 2.97 6 0.56 0.007*
MLD before PTCA (mm) 0.90 6 0.38 1.00 6 0.39 0.20*
%Stenosis before PTCA 66 6 12 64 6 12 0.27*
Stent type
Palmaz-Schatz 17 (46%) 54 (50%)
AVE 9 (24%) 24 (22%)
0.97‡NIR 9 (24%) 24 (22%)
Freedom 2 (5%) 5 (5%) }
MLD after procedure (mm) 2.35 6 0.40 2.56 6 0.45 0.01*
%Stenosis after stent 19 6 11 17 6 9 0.32*
Stent lumen CSA (mm2) after procedure 6.34 6 1.40 7.90 6 2.50 0.0002*
Early gain (mm) 1.45 6 0.49 1.57 6 0.48 0.21*
Late loss (mm) 0.66 6 0.42 1.47 6 0.50 ,0.0001*
Net gain (mm) 0.91 6 0.55 0.02 6 0.50 ,0.0001*
IVUS guidance 16 (43%) 55 (51%) 0.45†
%IVUS criterion achieved 26 (70%) 72 (67%) 0.83†
*Result of the Student t test. †Result of the Fisher exact probabilities test. ‡Result of the likelihood ratio chi-square
test. Data are presented as mean value 6 SD or number (%) of patients. Abbreviations as in Tables 1 and 2.
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Higher gains in lumen area or MLD have been previously
reported, but with very different stenting policies and IVUS
criterion. Nakamura et al. (4), in a first report, showed that
88% of patients in their series needed overdilation, which
resulted in an average 30% increase in intrastent lumen CSA.
A further report on a larger series by the same group (8)
confirmed that an average 35% increase in intrastent lumen
CSA was obtained by overdilation. However, these results were
achieved with very aggressive criteria for optimal stent deploy-
ment, which led to an aggressive overdilation strategy, result-
ing in negative residual stenosis (29 6 15%) (i.e., intrastent
MLD oversized with regard to the diameter of the reference
segment), and a 5.7% procedural complication rate and 1.2%
coronary artery rupture. With increasing experience, less ag-
gressive criterion for optimal stent deployment and more
appropriate balloon sizing (1.05 6 0.14 average balloon/artery
ratio), the procedural complication rate was reduced to 1%
(0% artery rupture), with 1% average final residual stenosis
(8). Following these initial reports, stenting policy and crite-
rion for optimal stent deployment have changed, with the ratio
of intrastent to reference lumen CSA with a cutoff point of 0.8
to 0.9 being now broadly adopted (12,19,21). As a result of this
modified IVUS guidance strategy, the IVUS criterion can be
achieved in the majority of patients relying only on the
angiographic appearance of the stented segment (19,21), so
that the anticipated gain obtained by IVUS-guided overdila-
tion is potentially reduced.
Impact on 6-month angiographic and IVUS end points. A
nonsignificant reduction in the restenosis rate was found in
Group B compared with Group A (22.5% vs. 28.8%, respec-
tively) (absolute difference 6.3 6 12%). However, the 95%
confidence interval was 26% to 18%, so that the hypothesis of
the study cannot be ruled out. Retrospective calculation of the
power of the study with regard to the primary end point
confirmed the lack of power with a beta risk of 60%.
There was a trend toward a larger MLD in Group B;
however, the difference was not significant. However, the
lumen size assessed using lumen CSA was significantly larger
in Group B at 6 months. Such angiographic and IVUS results
were also observed after stent implantation (a larger stent
lumen CSA was observed in Group B, without a significant
difference in MLD). This confirms the higher sensitivity of
IVUS measurements in assessing lumen size. At 6-month
follow-up, a 20% difference in lumen CSA was observed
between both groups (4.47 6 2.59 mm2 in Group A vs. 5.36 6
2.81 mm2 in Group B, p 5 0.03).
Predictors of 6-month restenosis. Postprocedure intrastent
MLD, lumen CSA, lesion site and reference diameter were
shown to be predictors of 6-month restenosis by univariate
analysis. By multivariate logistic regression analysis, lumen
CSA was shown to be the only independent predictor of
6-month restenosis (OR 0.70 6 0.23, p 5 0.007). This finding
is consistent with previous observations showing that lumen
CSA was a predictor of 6-month angiographic results and
target lesion revascularization rate (12–14,21). Moreover, post-
procedure lumen CSA was significantly correlated with the
6-month intrastent lumen CSA. Based on this observation, and
on the larger postprocedure lumen CSA observed in Group B,
one can reasonably assume that the IVUS guidance might
favorably affect the 6-month results.
Study limitations. The sample size was calculated accord-
ing to the hypothesis that there would be an absolute 15%
difference in the restenosis rate between the two groups (30%
vs. 15%), despite the fact that there was no evidence in
previous studies to suggest that such a difference between the
two groups could be expected. However, it was deemed
necessary by the investigators to adopt such a large difference
to compensate for the increased complexity and cost of the
procedure and to justify the routine use of this technique. The
main disadvantage of such an approach is the lack of statistical
power.
The other limitation of this study was that four different
types of stents were used, each with a different design and a
different recommended implantation pressure. However, nei-
ther univariate nor multivariate analysis showed any evidence
that stent type had an influence on the immediate or long-term
results.
Clinical implications. The 19.9% increase in late lumen
CSA, obtained with IVUS-guided stent implantation com-
pared with the angiography-based stenting strategy, may be
offset by the extra cost induced by the use of IVUS (22).
However, given the increasing rate of stenting, one can antic-
ipate encountering in the near future a growing rate of
intrastent restenosis, which to date is one of the most challeng-
ing problems in interventional cardiology (23). IVUS-guided
overdilation might then be worth considering, whatever the
magnitude of the gain that can be anticipated with this
technique.
We are indebted to Sophie Boucher and Fiona Caulfield for their help in
preparing the manuscript, and to Denis Pales Espinosa for data management.
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